β-Amyloid Load on PET Along the Continuum of Dementia With Lewy Bodies
暂无分享,去创建一个
David T. Jones | C. Jack | J. Gunter | J. Graff‐Radford | T. Ferman | S. Przybelski | T. Lesnick | M. Senjem | V. Lowe | K. Kantarci | C. Schwarz | D. Knopman | Hoon-Ki Min | R. C. Petersen | V. Ramanan | N. Graff-Radford | Dennis Dickson | R. Savica | G. Day | E. S. St. Louis | H. Botha | J. Fields | O. Ross | L. Forsberg | B. Boeve | Manoj K. Jain | T. Miyagawa | Patricia Diaz-Galvan
[1] David T. Jones,et al. β-Amyloid PET and 123I-FP-CIT SPECT in Mild Cognitive Impairment at Risk for Lewy Body Dementia , 2021, Neurology.
[2] C. Jack,et al. β-Amyloid and tau biomarkers and clinical phenotype in dementia with Lewy bodies , 2020, Neurology.
[3] Alan J. Thomas,et al. Research criteria for the diagnosis of prodromal dementia with Lewy bodies , 2020, Neurology.
[4] M. Yun,et al. Dopaminergic Depletion, β‐Amyloid Burden, and Cognition in Lewy Body Disease , 2020, Annals of neurology.
[5] Alan J. Thomas,et al. Amyloid Imaging and Longitudinal Clinical Progression in Dementia With Lewy Bodies. , 2019, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.
[6] David T. Jones,et al. β-Amyloid PET and neuropathology in dementia with Lewy bodies , 2019, Neurology.
[7] C. Jack,et al. Association of Longitudinal β-Amyloid Accumulation Determined by Positron Emission Tomography With Clinical and Cognitive Decline in Adults With Probable Lewy Body Dementia , 2019, JAMA network open.
[8] N. Okamura,et al. Assessment of Amyloid Deposition in Patients With Probable REM Sleep Behavior Disorder as a Prodromal Symptom of Dementia With Lewy Bodies Using PiB-PET , 2019, Front. Neurol..
[9] Yves Dauvilliers,et al. Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre study , 2019, Brain : a journal of neurology.
[10] C. Jack,et al. White Matter Reference Region in PET Studies of 11C-Pittsburgh Compound B Uptake: Effects of Age and Amyloid-β Deposition , 2018, The Journal of Nuclear Medicine.
[11] R. Petersen,et al. APOE ε4 is associated with severity of Lewy body pathology independent of Alzheimer pathology , 2018, Neurology.
[12] Alan J. Thomas,et al. Revision of assessment toolkits for improving the diagnosis of Lewy body dementia: The DIAMOND Lewy study , 2018, International journal of geriatric psychiatry.
[13] J. Graff‐Radford,et al. The limbic and neocortical contribution of α-synuclein, tau, and amyloid β to disease duration in dementia with Lewy bodies , 2018, Alzheimer's & Dementia.
[14] Yue Huang,et al. Reader response: Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium , 2018, Neurology.
[15] Alan J. Thomas,et al. Neuropsychiatric symptoms and cognitive profile in mild cognitive impairment with Lewy bodies , 2018, Psychological Medicine.
[16] R. Postuma,et al. How does dementia with Lewy bodies start? prodromal cognitive changes in REM sleep behavior disorder , 2017, Annals of neurology.
[17] B. Dickerson,et al. Multimodal PET Imaging of Amyloid and Tau Pathology in Alzheimer Disease and Non-Alzheimer Disease Dementias. , 2017, PET clinics.
[18] David T. Jones,et al. Defining imaging biomarker cut points for brain aging and Alzheimer's disease , 2017, Alzheimer's & Dementia.
[19] T. Montine,et al. Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis , 2017, The Lancet Neurology.
[20] J. Galvin. Improving the clinical detection of Lewy body dementia with the Lewy body composite risk score , 2015, Alzheimer's & dementia.
[21] Karen M Rodrigue,et al. Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis. , 2015, JAMA.
[22] Alan J. Thomas,et al. Neuropathologically mixed Alzheimer’s and Lewy body disease: burden of pathological protein aggregates differs between clinical phenotypes , 2015, Acta Neuropathologica.
[23] M. Sabbagh,et al. Clinical Characterization of Mild Cognitive Impairment as a Prodrome to Dementia With Lewy Bodies , 2015, American journal of Alzheimer's disease and other dementias.
[24] Keith A. Johnson,et al. Brain amyloid and cognition in Lewy body diseases , 2012, Movement disorders : official journal of the Movement Disorder Society.
[25] A. Fagan,et al. APOE predicts amyloid‐beta but not tau Alzheimer pathology in cognitively normal aging , 2010, Annals of neurology.
[26] Keith A. Johnson,et al. Imaging amyloid deposition in Lewy body diseases , 2008, Neurology.
[27] V. Pankratz,et al. The Mayo Clinic Study of Aging: Design and Sampling, Participation, Baseline Measures and Sample Characteristics , 2008, Neuroepidemiology.
[28] M. Onofrj,et al. Diagnosis and management of dementia with Lewy bodies: Third report of the DLB Consortium , 2006, Neurology.
[29] R. Petersen. Mild cognitive impairment as a diagnostic entity , 2004, Journal of internal medicine.
[30] C. P. Hughes,et al. A New Clinical Scale for the Staging of Dementia , 1982, British Journal of Psychiatry.
[31] S. Folstein,et al. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.
[32] C. Heitz,et al. Diagnostic Value of Cerebrospinal Fluid Biomarkers (Phospho-Tau181, total-Tau, Aβ42, and Aβ40) in Prodromal Stage of Alzheimer's Disease and Dementia with Lewy Bodies. , 2016, Journal of Alzheimer's disease : JAD.
[33] E. Tangalos,et al. Mayo's older americans normative studies: WAIS-R norms for ages 56 to 97 , 1992 .